Cargando…
Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis
This study aimed to compare the effects of abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) with those of combined androgen blockade (CAB) therapy in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). This study retrospectively identified 1...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724311/ https://www.ncbi.nlm.nih.gov/pubmed/34993133 http://dx.doi.org/10.3389/fonc.2021.769068 |
_version_ | 1784625895597670400 |
---|---|
author | Matsumura, Naoki Fujita, Kazutoshi Nishimoto, Mitsuhisa Yamamoto, Yutaka Kuwahara, Ken Nagai, Yasuharu Minami, Takafumi Hatanaka, Yuji Nozawa, Masahiro Morimoto, Yasuhiro Tahara, Hideo Uejima, Shigeya Esa, Atsunobu Hirayama, Akihide Yoshimura, Kazuhiro Uemura, Hirotsugu |
author_facet | Matsumura, Naoki Fujita, Kazutoshi Nishimoto, Mitsuhisa Yamamoto, Yutaka Kuwahara, Ken Nagai, Yasuharu Minami, Takafumi Hatanaka, Yuji Nozawa, Masahiro Morimoto, Yasuhiro Tahara, Hideo Uejima, Shigeya Esa, Atsunobu Hirayama, Akihide Yoshimura, Kazuhiro Uemura, Hirotsugu |
author_sort | Matsumura, Naoki |
collection | PubMed |
description | This study aimed to compare the effects of abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) with those of combined androgen blockade (CAB) therapy in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). This study retrospectively identified 163 patients with high-risk mHSPC at Kindai University and affiliated hospitals between January 2014 and December 2020. Kaplan-Meier analysis was used to summarize progression-free survival (PFS) and overall survival (OS). Multivariate Cox proportional hazard modeling was used to identify the prognostic factors in the overall cohort. Propensity score matching was used to adjust the clinical characteristics, and log-rank test was applied to these propensity score–matched cohorts. Seventy-four patients who received AAP with ADT and 89 patients who received CAB were included in this study. The median follow-up duration was 27 months (range, 2–89 months). The median PFS and OS were not reached by the AAP+ADT group and 15 and 79 months, respectively, in the CAB group. The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score and AAP+ADT were significant prognostic factors for PFS, whereas ECOG PS score, visceral metastasis, and AAP+ADT were significant prognostic factors for OS. The 2-year PFS was 76.1% in the AAP+ADT group and 38.6% in the CAB group (P < 0.0001), and the 2-year OS was 90.2% in the AAP+ADT group and 84.8% in the CAB group (P = 0.015). In conclusion, AAP+ADT had better PFS and OS than CAB in patients with high-risk mHSPC. |
format | Online Article Text |
id | pubmed-8724311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87243112022-01-05 Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis Matsumura, Naoki Fujita, Kazutoshi Nishimoto, Mitsuhisa Yamamoto, Yutaka Kuwahara, Ken Nagai, Yasuharu Minami, Takafumi Hatanaka, Yuji Nozawa, Masahiro Morimoto, Yasuhiro Tahara, Hideo Uejima, Shigeya Esa, Atsunobu Hirayama, Akihide Yoshimura, Kazuhiro Uemura, Hirotsugu Front Oncol Oncology This study aimed to compare the effects of abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) with those of combined androgen blockade (CAB) therapy in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). This study retrospectively identified 163 patients with high-risk mHSPC at Kindai University and affiliated hospitals between January 2014 and December 2020. Kaplan-Meier analysis was used to summarize progression-free survival (PFS) and overall survival (OS). Multivariate Cox proportional hazard modeling was used to identify the prognostic factors in the overall cohort. Propensity score matching was used to adjust the clinical characteristics, and log-rank test was applied to these propensity score–matched cohorts. Seventy-four patients who received AAP with ADT and 89 patients who received CAB were included in this study. The median follow-up duration was 27 months (range, 2–89 months). The median PFS and OS were not reached by the AAP+ADT group and 15 and 79 months, respectively, in the CAB group. The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score and AAP+ADT were significant prognostic factors for PFS, whereas ECOG PS score, visceral metastasis, and AAP+ADT were significant prognostic factors for OS. The 2-year PFS was 76.1% in the AAP+ADT group and 38.6% in the CAB group (P < 0.0001), and the 2-year OS was 90.2% in the AAP+ADT group and 84.8% in the CAB group (P = 0.015). In conclusion, AAP+ADT had better PFS and OS than CAB in patients with high-risk mHSPC. Frontiers Media S.A. 2021-12-21 /pmc/articles/PMC8724311/ /pubmed/34993133 http://dx.doi.org/10.3389/fonc.2021.769068 Text en Copyright © 2021 Matsumura, Fujita, Nishimoto, Yamamoto, Kuwahara, Nagai, Minami, Hatanaka, Nozawa, Morimoto, Tahara, Uejima, Esa, Hirayama, Yoshimura and Uemura https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Matsumura, Naoki Fujita, Kazutoshi Nishimoto, Mitsuhisa Yamamoto, Yutaka Kuwahara, Ken Nagai, Yasuharu Minami, Takafumi Hatanaka, Yuji Nozawa, Masahiro Morimoto, Yasuhiro Tahara, Hideo Uejima, Shigeya Esa, Atsunobu Hirayama, Akihide Yoshimura, Kazuhiro Uemura, Hirotsugu Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis |
title | Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis |
title_full | Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis |
title_fullStr | Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis |
title_full_unstemmed | Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis |
title_short | Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis |
title_sort | comparison of abiraterone and combined androgen blockade therapy for high-risk metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724311/ https://www.ncbi.nlm.nih.gov/pubmed/34993133 http://dx.doi.org/10.3389/fonc.2021.769068 |
work_keys_str_mv | AT matsumuranaoki comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT fujitakazutoshi comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT nishimotomitsuhisa comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT yamamotoyutaka comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT kuwaharaken comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT nagaiyasuharu comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT minamitakafumi comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT hatanakayuji comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT nozawamasahiro comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT morimotoyasuhiro comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT taharahideo comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT uejimashigeya comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT esaatsunobu comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT hirayamaakihide comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT yoshimurakazuhiro comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis AT uemurahirotsugu comparisonofabirateroneandcombinedandrogenblockadetherapyforhighriskmetastatichormonesensitiveprostatecancerapropensityscorematchedanalysis |